Jazz Pharmaceuticals plc reiterated revenue guidance for the full year 2022. The company reiterates top line revenue guidance of $3.5 billion to $3.7 billion for the year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
120.4 USD | -0.07% | -2.97% | -2.10% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.10% | 7.51B | |
+33.46% | 701B | |
+26.24% | 570B | |
+0.93% | 381B | |
+21.03% | 334B | |
+17.51% | 322B | |
+2.95% | 212B | |
+0.74% | 209B | |
-6.05% | 205B | |
-3.61% | 157B |
- Stock
- Equities
- Stock Jazz Pharmaceuticals plc - Nasdaq
- News Jazz Pharmaceuticals plc
- Jazz Pharmaceuticals plc Reiterates Revenue Guidance for the Full Year 2022